GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ENDRA Life Sciences
ENDRA Life Sciences is developing technology for liver ultrasound diagnostics. Its share price is a venture bet that its technology will become an affordable alternative to other diagnostic methods.
Share prices of companies in the market segment - Pharma liver
ENDRA Life Sciences is developing a thermoacoustic imaging technology for noninvasively assessing liver fat content, which is important for diagnosing NAFLD. We've categorized it under "Pharma: Liver." The chart below shows how the market is evaluating new medical diagnostic methods.
Broad Market Index - GURU.Markets
ENDRA Life Sciences is a medical device company developing technology for non-invasive ultrasound diagnostics of liver diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the medical device sector.
Change in the price of a company, segment, and market as a whole per day
NDRA - Daily change in the company's share price ENDRA Life Sciences
For ENDRA Life Sciences Inc., a developer of ultrasound technology, daily volatility reflects sensitivity to news of FDA approval. This metric is key to assessing the risk of its liver disease diagnostic system.
Daily change in the price of a set of shares in a market segment - Pharma liver
ENDRA Life Sciences is developing ultrasound technology for liver assessment, aiming to offer a non-invasive alternative to biopsy. The diagnostic equipment segment is extremely sensitive to trial results and regulatory approvals. The chart below shows the average daily volatility in this industry, serving as a backdrop for assessing NDRA's stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
ENDRA Life Sciences develops ultrasound technology for liver disease diagnostics. This innovative medtech company's shares are responding to clinical successes and regulatory decisions. Its history reflects the medtech sector's contribution to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ENDRA Life Sciences
For ENDRA Life Sciences, the year's performance is a story about the development of its non-invasive liver diagnostic system. Its 12-month market cap depends entirely on progress in obtaining regulatory approvals. The success of its thermoacoustic technology could offer a safe and affordable alternative to biopsy for assessing fatty liver disease.
Annual dynamics of market capitalization of the market segment - Pharma liver
ENDRA, a company developing technology for the non-invasive assessment of fatty liver disease, is betting on medical innovation. Its performance relative to the sector will reveal the extent to which investors believe in its ability to commercialize its unique technology and secure regulatory approval.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ENDRA Life Sciences, with its liver diagnostic device, is a medtech startup on its way to the market. Its performance relative to the S&P 500 reflects pending regulatory approval. A positive decision would be a powerful catalyst, capable of sending the stock outperforming the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ENDRA Life Sciences
ENDRA is a medical device company developing a liver ultrasound diagnostic system. Its monthly performance reflects progress in commercializing its technology. Regulatory approvals and initial sales are key milestones.
Monthly dynamics of market capitalization of the market segment - Pharma liver
The non-invasive liver diagnostics market is a promising area with the potential to transform treatment approaches. The dynamics of this sector, shown in the graph, reflect the speculative interest in new technologies. Companies like ENDRA Life Sciences are developing this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ENDRA Life Sciences, a diagnostic equipment developer, is betting on innovation in medical technology. The company's shares are driven by news of its technology implementations rather than by general market trends, creating an independent profile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ENDRA Life Sciences
ENDRA Life Sciences is developing an ultrasound technology for liver disease diagnostics that could become an alternative to biopsy. Its weekly stock price performance reflects progress in obtaining regulatory approvals and data confirming the accuracy of its method.
Weekly dynamics of market capitalization of the market segment - Pharma liver
ENDRA Life Sciences is developing ultrasound technology that aims to aid in the non-invasive diagnosis of liver diseases. This represents a potentially large market. The chart below shows how investors view its technology compared to other diagnostic equipment manufacturers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ENDRA Life Sciences is developing ultrasound technology. This is a potentially large market. The chart below shows how investors view its technology compared to other diagnostic equipment manufacturers and the broader market.
Market capitalization of the company, segment and market as a whole
NDRA - Market capitalization of the company ENDRA Life Sciences
ENDRA Life Sciences' market capitalization chart reflects investors' bets on its liver disease diagnostic technology. Its performance reflects the market's faith in its TAEUS system, which uses ultrasound to measure liver fat. Its low price reflects the long and arduous road to FDA approval and commercialization.
NDRA - Share of the company's market capitalization ENDRA Life Sciences within the market segment - Pharma liver
ENDRA Life Sciences is developing ultrasound diagnostic technology designed to assess the severity of fatty liver disease. Its market share in the medical device sector is small, but it's addressing a huge problem. Its capitalization is betting on its TAEUS system, which could become a low-cost alternative to MRI.
Market capitalization of the market segment - Pharma liver
This graph shows the total value of the entire biotech sector focused on liver diseases. For ENDRA, with its ultrasound technology for assessing fatty liver disease, this line represents a "silent epidemic." The rising graph reflects awareness of the scale of the problem and the enormous need for non-invasive and accessible diagnostic methods for this condition.
Market capitalization of all companies included in a broad market index - GURU.Markets
ENDRA Life Sciences is developing ultrasound diagnostic technology that should aid in assessing the severity of fatty liver disease. Its goal is to evaluate non-invasive diagnostics for a widespread problem.
Book value capitalization of the company, segment and market as a whole
NDRA - Book value capitalization of the company ENDRA Life Sciences
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing fatty liver disease. Its book value is its scientific and financial capital. It consists of patents and funds allocated to bring the TAEUS system to market. How has this capital changed? The chart below shows.
NDRA - Share of the company's book capitalization ENDRA Life Sciences within the market segment - Pharma liver
ENDRA Life Sciences is developing technology for liver ultrasound diagnostics. Its innovations require a material base: R&D centers to develop its TAEUS system and manufacturing facilities to assemble it. The chart shows its share of the physical infrastructure needed to create the next generation of diagnostic equipment.
Market segment balance sheet capitalization - Pharma liver
ENDRA Life Sciences is a medical diagnostics company. Its model is knowledge-intensive in a capital-intensive industry. Its asset portfolio is enormous. ENDRA invests in R&D to create its unique diagnostic device.
Book value of all companies included in the broad market index - GURU.Markets
ENDRA Life Sciences' assets are not drugs, but a team of engineers developing technology for the non-invasive assessment of fatty liver disease using ultrasound machines. Its book value reflects its research-intensive potential in medical diagnostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ENDRA Life Sciences
ENDRA Life Sciences is developing an ultrasound system for assessing fatty liver disease. Its market value is based on its technology and its potential to offer a non-invasive and affordable alternative to biopsy.
Market to book capitalization ratio in a market segment - Pharma liver
ENDRA Life Sciences is developing a non-invasive technology for diagnosing liver diseases using ultrasound. The chart shows how investors assess its potential to offer a cheaper and safer alternative to existing diagnostic methods.
Market to book capitalization ratio for the market as a whole
ENDRA Life Sciences develops technology for ultrasound diagnostics of liver diseases. This is an innovative approach to medical imaging. The company's market value reflects the potential of its technology to become a new standard. This chart shows how investors value non-invasive and affordable diagnostic solutions.
Debts of the company, segment and market as a whole
NDRA - Company debts ENDRA Life Sciences
ENDRA, a company developing ultrasound technology for assessing fatty liver disease, is in the commercialization phase. It is raising capital to obtain regulatory approvals and expand sales. This chart shows the financial costs of bringing this new diagnostic technology to market.
Market segment debts - Pharma liver
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using a standard ultrasound machine. This chart illustrates how the commercialization-stage company is funding its R&D and sales efforts to make its technology accessible to physicians and compete with other diagnostic methods.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ENDRA Life Sciences
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using standard ultrasound equipment. Bringing a new diagnostic application to market using existing equipment requires clinical trials and marketing. This chart shows how the company is using debt to commercialize its innovation.
Market segment debt to market segment book capitalization - Pharma liver
ENDRA Life Sciences develops ultrasound technology that allows for non-invasive measurement of liver fat. This chart shows how the medical device company finances its R&D and regulatory approvals. It compares its debt load to the overall medical device industry market capitalization.
Debt to book value of all companies in the market
ENDRA Life Sciences is developing ultrasound diagnostic technology that aims to aid in the early detection of liver disease. Bringing new medical equipment to market is a long and expensive process. How heavily is the company reliant on debt? This graph of total debt in the economy helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - ENDRA Life Sciences
ENDRA Life Sciences is developing thermoacoustic imaging technology to assess liver fat content, offering a non-invasive alternative to biopsy. This chart shows how investors value its diagnostic tool. The valuation is contingent on regulatory approval and commercialization.
P/E of the market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing fatty liver disease, offering a noninvasive alternative to biopsy. This graph illustrates the average assessment in the pharmaceutical and liver diagnostics sectors, where there is a significant need for accurate and safe diagnostic methods.
P/E of the market as a whole
ENDRA Life Sciences Inc. develops technology to improve the capabilities of ultrasound machines, specifically for the non-invasive assessment of fatty liver disease. This chart reflects the overall sentiment in the medical technology sector. It helps us understand whether NDRA's rating reflects confidence in its diagnostic technology or whether it is moving in line with broader industry trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ENDRA Life Sciences
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using an advanced ultrasound system. This could become an affordable alternative to expensive diagnostic methods. This chart demonstrates the investors' confidence in the commercial potential of this diagnostic technology and its widespread adoption.
%20P%2FE%20ENDRA%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ENDRA-Life-Sciences&v=1772646649853 "Chart of the company's future (projected) P/E ENDRA Life Sciences")
Future (projected) P/E of the market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing fatty liver disease, offering a non-invasive alternative to biopsy. The chart reflects future revenue forecasts for the sector, helping to understand the extent to which investors believe this diagnostic system will become the new standard in hepatology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772646649860 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
ENDRA Life Sciences is developing ultrasound technology that aims to aid in the early, non-invasive diagnosis of liver disease. This healthcare market sentiment chart helps understand how investors view the prospects of technologies that expand the capabilities of existing diagnostic platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646649898 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ENDRA Life Sciences
ENDRA Life Sciences is developing technology for ultrasound machines that quantifies liver fat content, which is essential for diagnosing NASH. Profits depend on the commercialization of this technology. This chart shows the company's financial trajectory as it strives to improve the diagnostic capabilities of widely used medical equipment.
Profit of companies in the market segment - Pharma liver
ENDRA Life Sciences Inc. is developing a technology for non-invasively assessing liver fat content using a modified ultrasound machine. This could become a simple tool for diagnosing NASH. This graph shows the overall profitability of the liver disease diagnostics sector, where creating an accessible and accurate screening method is a major medical challenge.
Overall market profit
ENDRA Life Sciences develops technology for ultrasound diagnostics of liver diseases. The company operates at the intersection of innovation and medicine. Its success depends on regulatory approvals and market acceptance of its technology. This process is independent of general economic cycles, which can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ENDRA Life Sciences
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing fatty liver disease, offering a noninvasive alternative to biopsy. Future revenue depends on the commercialization of this diagnostic system. This graph reflects analysts' expectations regarding its breakthrough potential in hepatology.
%20profit%20of%20the%20company%20ENDRA%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ENDRA-Life-Sciences&v=1772646650002 "Graph of future (projected) profit of the company ENDRA Life Sciences")
Future (predicted) profit of companies in the market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging technology for the assessment of fatty liver disease, offering a more affordable alternative to MRI. Early diagnosis of this condition is crucial. This graph shows revenue expectations for the liver disease treatment sector, helping to assess the potential of the ENDRA diagnostic system.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772646650019 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
ENDRA Life Sciences is developing a technology for non-invasive diagnostics of liver diseases using ultrasound. The company's success depends on the commercialization and adoption of its technology. This economic outlook influences the willingness of healthcare systems to invest in new diagnostic equipment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646650028 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ENDRA Life Sciences
ENDRA Life Sciences is developing an ultrasound diagnostic technology that aims to aid in the early detection of liver diseases. Revenue will be a key metric during the commercialization phase. This chart reflects investor expectations regarding the technology and its potential.
P/S market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging (TAEUS) technology for the non-invasive assessment of fatty liver disease. This technology could become a cheaper and more accessible alternative to MRI, simplifying the diagnosis of this common disease. This chart shows the average revenue estimate for the sector, helping to assess the potential of this innovation.
P/S of the market as a whole
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using a standard ultrasound machine. This chart highlights that the value of such diagnostic companies depends on their ability to make diagnosis of this serious disease more accessible and affordable.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ENDRA Life Sciences
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using existing ultrasound equipment. Estimating future revenue is important for such a diagnostic company, as it indicates how investors view the potential of its technology to become an accessible and widely used screening tool for this common liver disease.
%20P%2FS%20ENDRA%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ENDRA-Life-Sciences&v=1772646650124 "The graph of the company's future (projected) P/S ENDRA Life Sciences")
Future (projected) P/S of the market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing fatty liver disease, offering a non-invasive alternative to biopsy. This chart compares the company's estimated future sales with expectations for the medical device sector. It shows whether investors believe its diagnostic system will become a significant tool in hepatology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772646650212 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
ENDRA Life Sciences is developing thermoacoustic imaging technology for assessing liver fat content, a non-invasive alternative to biopsy. The company's success depends on the commercialization of this diagnostic system. This graph of investor expectations reflects their belief that new imaging methods will improve the diagnosis of chronic diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646650269 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ENDRA Life Sciences
This figure for ENDRA Life Sciences reflects the financial activity of the company, which is developing an ultrasound system for the non-invasive assessment of fatty liver disease. Revenues may be modest during the commercialization phase, and future growth depends on the approval and adoption of the technology.
Sales of companies in the market segment - Pharma liver
ENDRA Life Sciences is developing a technology for non-invasive diagnostics of liver diseases using ultrasound. While in the commercialization stage, its revenue will come from sales of its TAEUS system. The sales mix will determine how successfully this new technology is adopted by the medical community.
Overall market sales
ENDRA Life Sciences Inc. is developing a technology for the non-invasive assessment of fatty liver disease using a standard ultrasound machine. This overall economics doesn't affect the enormous need for simpler and more accessible diagnostics for this common disease, which is ENDRA's primary driver.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ENDRA Life Sciences
ENDRA Life Sciences is developing thermoacoustic imaging (TAEUS) technology for the non-invasive assessment of fatty liver disease, providing an alternative to biopsy. Future revenues depend on the commercialization of this diagnostic system. This chart shows analysts' expectations for demand for their innovative liver disease diagnostic solution.
%20sales%20of%20the%20company%20ENDRA%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ENDRA-Life-Sciences&v=1772646650572 "Schedule of future (projected) sales of the company ENDRA Life Sciences")
Future (projected) sales of companies in the market segment - Pharma liver
ENDRA Life Sciences is developing ultrasound diagnostic technology aimed at assessing fatty liver disease. This chart illustrates the diagnostic equipment market forecast. Is the demand for non-invasive and affordable diagnostic methods for common diseases growing? This determines the overall outlook.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772646650606 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
ENDRA Life Sciences is developing technology for the non-invasive assessment of fatty liver disease. Demand for its diagnostic equipment will depend on its clinical effectiveness, regulatory approval, and acceptance by the medical community. This overall economic activity schedule does not impact the growing need for liver disease diagnostics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646650718 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ENDRA Life Sciences
ENDRA Life Sciences is developing a non-invasive tissue imaging technology using thermoacoustics, aimed at diagnosing liver diseases. This graph shows the company's path to commercialization. Commercialization depends on regulatory approvals and whether its system can become an affordable and accurate alternative to existing diagnostic methods.
Market segment marginality - Pharma liver
ENDRA Life Sciences Inc. is developing a technology for non-invasively assessing liver fat content using ultrasound. This chart reflects the company's financial performance during the development and commercialization phase, where profitability depends on regulatory approvals and the implementation of its technology in clinical practice.
Market marginality as a whole
ENDRA Life Sciences is developing a technology for the non-invasive assessment of fatty liver disease using ultrasound. Its success depends on the commercialization of this technology. This gross profitability chart reflects the state of the medical device industry and the willingness of clinics to invest in new diagnostic tools.
Employees in the company, segment and market as a whole
Number of employees in the company ENDRA Life Sciences
ENDRA Life Sciences is developing technology for the non-invasive assessment of fatty liver disease using ultrasound. Its team of engineers and scientists is its greatest asset. This chart shows how the company is investing in personnel to complete the development of its TAEUS product and obtain regulatory approvals for its market launch.
Share of the company's employees ENDRA Life Sciences within the market segment - Pharma liver
ENDRA Life Sciences is developing ultrasound technology that aims to aid in the early, non-invasive diagnosis of liver disease. Creating such a complex diagnostic tool is a challenge for a team of engineers and scientists. This chart shows the company's market share, reflecting the scale of its R&D efforts and the stage of product development.
Number of employees in the market segment - Pharma liver
ENDRA Life Sciences is developing thermoacoustic imaging technology to assess liver fat content, offering a noninvasive alternative to biopsy. The chart reflects employment in the liver pharmaceutical sector. This technology could become an important tool for diagnosing nonalcoholic fatty liver disease.
Number of employees in the market as a whole
ENDRA Life Sciences is developing a non-invasive thermoacoustic tissue imaging technology aimed at diagnosing liver diseases. The company's growth depends on the commercialization of this innovation. This chart shows the big picture, and ENDRA is an example of how breakthrough diagnostic technologies can create a new market and jobs for engineers and medical professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ENDRA Life Sciences (NDRA)
ENDRA Life Sciences is developing a diagnostic ultrasound system (TAEUS) for the early detection and monitoring of fatty liver disease. This is a medical R&D company. This chart shows how the market values their IP. It reflects the high market value per engineer, reflecting their unique diagnostic technology.
%20of%20the%20company%20ENDRA%20Life%20Sciences%20(NDRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ENDRA-Life-Sciences-NDRA&v=1772646651150 "Chart of market capitalization per employee (in thousands of dollars) of the company ENDRA Life Sciences (NDRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
ENDRA Life Sciences (NDRA) is developing a technology for non-invasive tissue imaging using thermoacoustics, aimed at diagnosing liver diseases. In the medical technology industry, this metric is a benchmark for their breakthrough technology. The high capitalization per employee suggests the potential of their system to become an affordable and safe alternative to liver biopsy.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772646651202 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
ENDRA Life Sciences is developing ultrasound diagnostic technology that aims to aid in the early detection of liver diseases. The company's value lies in its innovation. The graph shows a high employee rating, as its technology can transform a standard ultrasound machine into a powerful diagnostic tool, creating a huge potential market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646651226 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ENDRA Life Sciences (NDRA)
ENDRA Life Sciences is developing a technology (TAEUS) for non-invasive liver diagnostics (similar to ultrasound, but for measuring fat). This is MedTech R&D. This chart shows the company is in the R&D and approval phase. The loss per employee reflects investments in engineers and physicians prior to commercialization.
%20Chart%20ENDRA%20Life%20Sciences%20(NDRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ENDRA-Life-Sciences-NDRA&v=1772646651242 "Company Profit Per Employee (in thousands of dollars) Chart ENDRA Life Sciences (NDRA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
ENDRA Life Sciences Inc. develops ultrasound technology aimed at the early detection of liver diseases. In the field of medical imaging, efficiency per employee reflects the value of their innovations. The graph shows the financial return generated by a team creating a more accessible and safe diagnostic tool.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772646651317 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
ENDRA Life Sciences (NDRA) is a medical technology company. They are developing a thermoacoustic ultrasound system (TAEUS) for ultrasound machines, which should aid in the diagnosis of liver diseases (NES). This is an R&D business. This chart, showing average market efficiency, helps to understand the contrast with R&D businesses, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646651336 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ENDRA Life Sciences (NDRA)
ENDRA Life Sciences is developing a technology for ultrasound diagnostics of fatty liver disease. This graph shows the path to commercialization of their innovative system. A sharp increase in revenue per employee will indicate successful implementation of their device in clinics, enabling a small team to generate significant revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ENDRA-Life-Sciences-NDRA&v=1772646651341 "Sales chart per company employee ENDRA Life Sciences (NDRA)")
Sales per employee in the market segment - Pharma liver
ENDRA Life Sciences (NDRA) is developing an innovative TAEUS diagnostic system for the assessment of fatty liver disease (NAFLD) as a non-invasive alternative. This medical technology is in the commercialization stage. This graph shows the average output in the sector. For ENDRA, this is an indicator of how productive their R&D and sales teams will be in promoting this new technology to physicians.
Sales per employee for the market as a whole
ENDRA Life Sciences (NDRA) is developing a technology (TAEUS) that aims to improve ultrasound machines by adding the ability to measure liver fat (for diagnosing NASH). This is an R&D business. This indicator reflects their pre-commercial phase: the company is working toward approval and implementation of its technology.
Short shares by company, segment and market as a whole
Shares shorted by company ENDRA Life Sciences (NDRA)
ENDRA (NDRA) is developing an ultrasound system for noninvasive liver fat assessment (NASH). This chart shows the volume of bearish bets. "Shorts" reflect a bet that the company's technology will fail to gain FDA approval or will prove inaccurate.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ENDRA-Life-Sciences-NDRA&v=1772646651406 "Short Shares Chart for the Company ENDRA Life Sciences (NDRA)")
Shares shorted by market segment - Pharma liver
ENDRA Life Sciences (NDRA) is developing a non-invasive thermoacoustic imaging (TAEUS) system for the assessment of fatty liver disease (NASH). This chart shows the total short position in the diagnostics sector. It reflects investor concerns about the lengthy and expensive FDA approval process.
Shares shorted by the overall market
ENDRA Life Sciences is developing an ultrasound system for diagnosing liver diseases. This medical technology competes with existing methods. This chart measures overall fear. When investors are fearful, they are skeptical of new diagnostic devices. They worry about slow market adoption and problems obtaining insurance coverage for NDRA.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ENDRA Life Sciences (NDRA)
This oscillator for ENDRA Life Sciences is a barometer of faith in its diagnostic technology. The company is developing the TAEUS system, a non-invasive "ultrasound biopsy" for assessing fatty liver disease. "Overheating" (above 70) occurs in anticipation of FDA approval. Years of delays in obtaining approval and a lack of cash keep the stock deeply "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ENDRA-Life-Sciences-NDRA&v=1772646651472 "RSI 14 indicator chart for the company's stock ENDRA Life Sciences (NDRA)")
RSI 14 Market Segment - Pharma liver
ENDRA Life Sciences is developing the innovative TAEUS system. This ultrasound device is designed for noninvasive liver fat measurement (NAFLD assessment), offering an alternative to biopsy. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how ENDRA compares to it.
RSI 14 for the overall market
ENDRA Life Sciences (NDRA) develops non-invasive diagnostic systems, specifically for assessing liver health. As a company bringing a new product to the medical device market, it relies on investment. This chart shows the overall market "temperature." When the market is "overheated," investors are more willing to fund innovation. During periods of panic (overselling), capital becomes expensive, slowing NDRA's commercialization.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NDRA (ENDRA Life Sciences)
ENDRA Life Sciences is a medical technology company developing the TAEUS system, a complementary ultrasound device for non-invasive liver fat measurement (NASH diagnostics). This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their belief in FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NDRA-ENDRA-Life-Sciences&v=1772646651527 "A chart showing analyst consensus forecasts for the expected stock price. NDRA (ENDRA Life Sciences)")
The difference between the consensus estimate and the actual stock price NDRA (ENDRA Life Sciences)
ENDRA is a medical technology company developing TAEUS, an ultrasound device designed to non-invasively measure fatty liver disease (MASH/NASH). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this new diagnostic technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NDRA-ENDRA-Life-Sciences&v=1772646651561 "A chart showing the difference between the consensus forecast and the actual stock price. NDRA (ENDRA Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
ENDRA is a MedTech startup developing "ultrasound 2.0." Its system (TAEUS) is designed to measure liver fat non-invasively (without biopsy). This chart reflects the general expectations of analysts across the liver pharma sector. It shows whether experts believe in a breakthrough in non-invasive NASH diagnostics.
Analysts' consensus forecast for the overall market share price
ENDRA Life Sciences is a medical company developing a technology (TAEUS) that should enable ultrasound machines to measure fatty liver disease (NASH). This graph shows the overall "risk appetite" in the market. For ENDRA, a company with an innovative but not yet approved technology, the overall optimism (the rising graph) is important for funding clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ENDRA Life Sciences
ENDRA Life Sciences is ultrasound 2.0 for the liver. Their signature feature is TAEUS, a device (an ultrasound add-on) that (they claim) can non-invasively (like ultrasound) measure liver fat (LFA), replacing expensive MRI. This chart summarizes their implementation history. It reflects their (very slow) path to FDA approval and their (uphill) struggle for commercialization.
AKIMA Market Segment Index - Pharma liver
ENDRA Life Sciences is developing a new ultrasound system (TAEUS) for the non-invasive assessment of fatty liver disease (NASH). This could replace painful and expensive biopsies. This represents a breakthrough in diagnostics. This graph compares their composite index with the sector, showing how their diagnostic innovation is ahead of the competition.
The AKIM Index for the overall market
ENDRA Life Sciences is a developer of thermoacoustic imaging technology (TAEUS), which enhances ultrasound capabilities (for example, for the liver). This chart, reflecting the market average, is a backdrop. It helps assess how NDRA, a diagnostic innovation, fits within the context of overall macroeconomic trends.
